This study is for patients with *uterine leiomyosarcoma*, a type of cancer in the uterus. The trial will test a medicine called **letrozole** (also known as Femara) to see if it helps patients live longer without the cancer getting worse. Participants will take a 2.5 mg pill of letrozole every day. The study is in its second phase, which means it is still being tested but has shown some promise in earlier trials.

• The study involves taking letrozole daily and may include regular check-ups to monitor progress.
• Participants need to be 18 or older, in good health, and have no other severe diseases or recent cancer treatments.
• The trial is not suitable for pregnant women or those who have taken certain hormone medicines recently.

*Progression-free survival* means living without the cancer spreading. *ER positivity* is when cancer cells have receptors that letrozole can target. Participants must have completed certain surgeries and meet specific health criteria. The study aims to see if letrozole can help stop the cancer from progressing. Participants should be able to swallow pills and must not have any known allergies to letrozole ingredients.